Depo Provera Lawsuit Update May 2026: Daubert and MDL 3140

Last Updated: July 16, 2026 | Reviewed by: Legal Lawsuit Editorial Team | Primary Sources: JPML MDL docket records, FDA drug safety records.

This Depo-Provera lawsuit update for May 2026 covers important developments for anyone who used Depo-Provera and was later diagnosed with a meningioma. MDL 3140, the consolidated federal litigation against Pfizer in the Northern District of Florida, has grown past 3,769 active cases and is moving through Daubert hearings that will shape every claim. Filing deadlines are also running now for women diagnosed in 2023 and early 2024, so acting quickly matters more than ever. Call 833-333-0905 or start your free Depo-Provera case evaluation today, before your filing window closes.

May 2026 Depo-Provera Lawsuit Update: Key Points

Here is where the Depo-Provera meningioma lawsuit stood heading into May 2026, and what it means for women who haven’t filed yet:

• More than 3,769 active cases in MDL 3140 as of May 2026, making it a large and growing pharmaceutical MDL
• Daubert hearings in progress, with the court weighing whether expert testimony on the Depo-Provera meningioma link is admissible
• A meningioma warning is now on the U.S. label, after Pfizer was required to update Depo-Provera labeling to disclose the risk
• Deadlines are running, and women diagnosed in 2023 or early 2024 may have under a year left to file in many states
• No public payout figures yet; the July 2026 Master Settlement Agreement has not released its tiers, and individual value depends on the injuries involved
• Settlement update: after this May 2026 report, Pfizer reached a global agreement in principle (June) and signed a Master Settlement Agreement for eligible claims (July 2026)

The Depo-Provera MDL also stands out for how varied its plaintiffs are: women of many ages, occupations and backgrounds who used the shot for birth control. Many only recently learned of the scientific evidence linking the injection to their meningioma, which is why Legal Lawsuit refreshes this page every month so no one misses a chance to pursue compensation through the Depo-Provera legal process.

MDL 3140 in May 2026: Status and Daubert Hearings

MDL 3140, formally In re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation, is being managed in the Northern District of Florida. The headline development right now is the Daubert phase, one of the most consequential stages of the case. In Daubert proceedings, the judge decides whether plaintiffs’ scientific experts meet the reliability standard to testify on causation, namely whether medroxyprogesterone acetate (MPA) causes meningioma beyond what chance would explain, using a sound, peer-reviewed methodology. Plaintiffs’ experts are expected to rely on the 2024 BMJ study, research on progesterone receptors in meningiomas, epidemiological cohort data and clinical reports of meningiomas shrinking after Depo-Provera is stopped. The FDA label change will likely feature prominently as well, since plaintiffs argue it shows the evidence of meningioma risk was strong enough to prompt regulatory action, supporting the failure-to-warn theory. A ruling in plaintiffs’ favor would open the door to bellwether trials, where a representative group of cases goes to verdict and sets a template for wider settlement, so the Daubert decision is the most important near-term event for every MDL 3140 plaintiff. Official information is available from the Judicial Panel on Multidistrict Litigation and CourtListener.

2026 Developments: FDA, Pfizer and the Court

Several important developments have shaped the Depo-Provera meningioma litigation in 2026, and they matter for judging where you stand. First, the FDA-required meningioma label change is now in effect: Pfizer’s prescribing information and patient materials now disclose the association between long-term MPA use and higher meningioma risk. That change doesn’t settle the litigation, but plaintiffs see it as a meaningful acknowledgment supporting their failure-to-warn claims. Second, Pfizer is turning over internal documents under MDL discovery orders, including pre-approval clinical data, post-market safety monitoring and internal communications about the meningioma signal, records expected to be central at the bellwether trials. Third, a bellwether pool has been chosen, and trial scheduling is expected to follow if the Daubert rulings favor plaintiffs. Those trials will offer the first look at how juries view Pfizer’s responsibility and what they consider fair compensation. Meanwhile, the FDA has paid growing attention to progestin safety overall, following regulators in France and elsewhere in Europe that restricted high-potency progestins or required stronger warnings years before the U.S. did. Plaintiffs say that history shows Pfizer should have acted sooner and that the delay harmed thousands of American women. Pfizer has also not announced a settlement fund or global resolution, so women who file now will be in the litigation when any settlement talks begin.

Depo-Provera Filing Deadlines You Can’t Afford to Miss

Filing deadlines are among the most important, and most misunderstood, parts of the Depo-Provera meningioma lawsuit. Here’s what to know as of May 2026:

• Most states: 2–3 years from your meningioma diagnosis, OR from when you learned (or reasonably should have learned) of the link to Depo-Provera
• Discovery rule: Many states delay the start of the clock until you knew or should have known about the drug connection, which may give more time to women diagnosed before the FDA warning
• Wrongful death: Deadlines differ by state and usually run from the date of death, not the injury deadline
• No automatic pause: Being part of an MDL does NOT toll individual state deadlines; you must file your own complaint to protect your rights
• Diagnosed in 2022–2023: Your deadline may be running out right now in many states, so talk to an attorney immediately

The biggest mistake a Depo-Provera meningioma patient can make is assuming there’s plenty of time. Statutes of limitations are strict, and once one passes, even a strong case can be barred for good. Call 833-333-0905 now or read our Depo-Provera lawsuit guide to confirm your deadline.

Who Can Still File a Depo-Provera Lawsuit in May 2026?

Many women with a Depo-Provera-linked meningioma can still file as of May 2026. The basic criteria haven’t changed: at least 12 months of Depo-Provera use, a confirmed meningioma of any grade, use that came before the diagnosis and a claim still within your state’s deadline. The pressure is mounting fast, though, for women diagnosed earlier.

• Diagnosed 2024–2026: Very likely still in time, but don’t wait
• Diagnosed 2023: The window is closing in most states, so contact an attorney now
• Diagnosed 2022: May be too late in some states without a discovery rule, so get legal advice urgently
• Diagnosed before 2022: Possibly time-barred in many states, though the discovery rule may save your claim if you only recently learned of the Depo-Provera link
• Wrongful death: Deadlines run from the date of death, so consult an attorney right away no matter when it happened

What Will Drive Depo-Provera Settlement Values in 2026

No global settlement had been announced as of May 2026 (Pfizer later signed a Master Settlement Agreement in July 2026), and Legal Lawsuit does not publish projected payout ranges or fund totals, because no verified figures exist. Individual values are expected to depend on the meningioma’s grade and location, whether it required surgery or radiation, lasting effects such as vision loss, seizures or cognitive problems, how long the shot was used, lost income, the outcome of the Daubert ruling and bellwether verdicts, and, in wrongful death cases, the losses to the family. For a rough personal estimate, try our free Depo-Provera settlement calculator, and see all mass tort settlement data on Legal Lawsuit. Attorneys in our network also review Ozempic lawsuits, talcum powder lawsuits and hair relaxer lawsuits.

How to Join the Depo-Provera Litigation in May 2026

1. Free Case Review: Call 833-333-0905 or apply online; it takes about five minutes and costs nothing.
2. Collecting Records: Your legal team helps get your Depo-Provera prescription history and meningioma imaging and pathology reports.
3. Hiring an MDL Attorney: Contingency fee only, with no fee unless you recover.
4. Filing in MDL 3140: Your complaint is filed in the Northern District of Florida, typically without you needing to appear in court.
5. Waiting for Resolution: Mass tort cases commonly take two to four years or more from filing to settlement or verdict.

Try Our Free Depo-Provera Settlement Calculator

Before calling, get a ballpark sense of your claim with our free Depo-Provera settlement calculator, which takes less than two minutes.

Depo-Provera Lawsuit Update 2026: Common Questions

About the Author

I’m Mason Arnao. My background in data systems, technology infrastructure and digital advocacy helps me explain how each Depo-Provera lawsuit update affects real people dealing with complicated legal and medical systems. As publisher of LegalLawsuit.com and President of Waypoint Software, a digital firm with more than 20 years of experience, I build systems that connect people with information they need. This page is refreshed monthly with the newest developments in the Depo-Provera meningioma litigation.